28 results
8-K
EX-10.7
TRML
Tourmaline Bio Inc
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
; workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate
424B3
TRML
Tourmaline Bio Inc
15 Sep 23
Prospectus supplement
6:31am
implemented a restructuring plan that included reducing its workforce by approximately one-third,
with remaining employees primarily focused … a further reduction in force that resulted in the termination of approximately 95% of Talaris’ remaining workforce. The workforce reductions were
S-4/A
7i0 sopz1
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
h0oi42swv
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
sul9m3vbx
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
q0rij2af54sc 6q
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
8-K
EX-99.1
tn9dwt0xrg1as
30 May 23
Talaris Therapeutics Announces Leadership Transition
4:51pm
8-K
122ty7z 32g
14 Apr 23
Cost Associated with Exit or Disposal Activities
5:20pm